ASH Annual Meeting and Exposition | Conference

Maintenance Teclistamab With or Without Lenalidomide Is Safe, Active in Newly Diagnosed Myeloma

December 9th 2024

Maintenance therapy with teclistamab with or without lenalidomide was safe and efficacious in newly diagnosed multiple myeloma.

Zilovertamab Vedotin Plus R-CHP Yields 97.2% Overall CR Rate in DLBCL

December 9th 2024

Patients with treatment naive DLBCL experienced high response rates when treated with zilovertamab vedotin plus R-CHP and a RP2D dose of the agent was selected.

Navtemadlin Reduces Markers of Disease Burden in Relapsed/Refractory Myelofibrosis

December 9th 2024

Treatment with navtemadlin lowered the levels of biomarkers of disease burden in patients with relapsed/refractory myelofibrosis.

Dr Siegel on the Preliminary Use of Mezigdomide in Relapsed/Refractory Myeloma

December 9th 2024

David Samuel Dicapua Siegel, MD, discusses preliminary findings from the phase 1/2 CA057-003 trial of mezigdomide in relapsed/refractory multiple myeloma.

Dr Foster on Daratumumab Plus Lenalidomide in Newly Diagnosed Myeloma After Transplant

December 9th 2024

Laahn Foster, MD, shares data on daratumumab and lenalidomide vs lenalidomide alone as maintenance in newly diagnosed multiple myeloma after transplant.

Fixed-Duration Acalabrutinib/Venetoclax Combo Improves PFS in Frontline CLL

December 8th 2024

Acalabrutinib plus venetoclax, with or without obinutuzumab, improved PFS over SOC chemoimmunotherapy in patients with treatment-naive CLL.

Liso-Cel Shows Broad Spectrum Activity in CIBMTR Cohort of Relapsed/Refractory LBCL

December 8th 2024

Liso-cel demonstrated safety and efficacy outcomes that were comparable to those in the pivotal TRANSFORM and PILOT trials in patients with relapsed/refractory large B-cell lymphoma.

Daratumumab Significantly Improves PFS, Extends OS in Smoldering Myeloma

December 8th 2024

Subcutaneous daratumumab reduced the risk for disease progression or death vs active monitoring in intermediate- or high-risk smoldering multiple myeloma.

Social Determinants of Health Correlate With Receipt of Allo-HSCT in AML

December 8th 2024

Social determinants of health have a more pronounced effect on mortality among patients with AML who did not receive transplant vs those who did.

Dr Mauz-Koerholz on the Role of Pembrolizumab in Younger Patients With Low-Risk Classic Hodgkin Lymphoma

December 8th 2024

Christine Mauz-Koerholz, MD, PhD, discusses updated results from the phase 2 KEYNOTE-667 trial, which were shared at the 2024 ASH Annual Meeting.

Brexu-Cel Displays Comparable Efficacy Across Age Groups in Relapsed/Refractory B-ALL

December 8th 2024

Brexucabtagene autoleucel demonstrated similar efficacy across age groups of patients with relapsed/refractory B-cell acute lymphoblastic leukemia

Asciminib Continues to Best SOC TKIs as Secondary End Points of ASC4FIRST Trial are Met

December 8th 2024

Treatment with asciminib results in superior efficacy and safety vs investigator-selected TKIs in CML according to updated 96-week data from ASC4FIRST.

Epcoritamab Monotherapy Induces Complete Responses in R/R CLL

December 8th 2024

Single-agent, subcutaneous epcoritamab generated deep responses in patients with relapsed/refractory chronic lymphocytic leukemia.

Olverembatinib May Be Effective in Second Line for CP-CML

December 8th 2024

Olverembatinib showed potential in patients with chronic-phase chronic myeloid leukemia with prior exposure to first-line second-generation TKIs.

US Real-World Analysis Supports Clinical Benefit of Tafasitamab in R/R DLBCL

December 8th 2024

Data from a retrospective analysis showcase the real-world effectiveness of tafasitamab for relapsed/refractory DLBCL in the United States.

FS118 Showcases Modest Efficacy in Relapsed/Refractory DLBCL

December 8th 2024

FS118, an investigational LAG-3/PD-L1 bispecific antibody, demonstrated an encouraging objective response rate in the relapsed/refractory DLBCL setting.

Dr Kaddoura on Genomic Determinants of Outcomes in IGH/CCND1+ Myeloma Treated With Venetoclax

December 8th 2024

Marcella Ali Kaddoura, MD, discusses genomic determinants of clinical outcomes in myeloma with t(11;14)(CCND1;IGH) treated with venetoclax.

Dr Zackon on the Use of Bispecific Antibodies in the Community Setting for R/R Myeloma

December 8th 2024

Ira Zackon, MD, discusses findings on the real-world utilization of bispecific antibodies in the treatment of relapsed/refractory multiple myeloma in the community oncology setting.

Dr Jurczak on the Efficacy and Safety of Nemtabrutinib in R/R Follicular Lymphoma

December 8th 2024

Wojciech Jurczak, MD, PhD, discusses the safety and efficacy of nemtabrutinib, a noncovalent reversible BTK inhibitor in relapsed or refractory follicular lymphoma.

Oral Revumenib-Based Combo Produces Responses in R/R AML

December 8th 2024

Revumenib plus decitabine/cedazuridine and venetoclax produced responses in relapsed/refractory acute myeloid leukemia.